Urgent Ramipril recall as blood pressure medication 'has wrong dosage'

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an urgent Class 1 National Patient Level Recall for specific batches of Ramipril 5mg tablets, a widely prescribed blood pressure medication, after an alarming discovery of incorrect dosages within packs. Manufactured by Auden Mckenzie, the mislabeled tablets pose a critical risk, with some 5mg packs found to contain 10mg tablets, potentially leading to severe hypotension or dangerously uncontrolled hypertension for thousands of patients relying on precise cardiovascular management. This immediate action underscores persistent vulnerabilities within the global pharmaceutical supply chain and manufacturing oversight, following a series of recent quality control breaches across the industry. The incident highlights a systemic breakdown in Good Manufacturing Practice (GMP) and Quality Control (QC) protocols at a time when regulatory bodies, including the MHRA, FDA, and EMA, are already intensifying scrutiny on drug purity and dosage accuracy in response to a global uptick in drug-related recalls. Patients are advised to immediately check their Ramipril batches against the MHRA guidance but crucially, not to cease medication without consulting a healthcare professional due to the severe risks of abrupt treatment discontinuation. Auden Mckenzie faces intense pressure to detail the root cause of the failure, with regulatory investigations expected to delve deep into their production lines and potentially trigger broader audits across the generics sector to restore public confidence in essential medicines.